Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

Core Viewpoint - Delcath Systems' CHEMOSAT Hepatic Delivery System significantly improves melanoma-specific survival in patients with liver metastases from uveal melanoma when used as a first-line therapy, as demonstrated in a recent clinical study [1][4]. Company Overview - Delcath Systems specializes in interventional oncology, focusing on primary and metastatic liver cancers, with key products including HEPZATO KIT and CHEMOSAT Hepatic Delivery System [3]. - The CHEMOSAT device is regulated as a Class III medical device in Europe [3]. Clinical Study Findings - A retrospective study analyzed 167 patients diagnosed between 2005 and 2021, revealing that those receiving liver-directed therapies, including CHEMOSAT, had a median melanoma-specific survival (MSS) of 28 months, compared to 10 months for those on systemic therapies [2][5]. - The MSS improved to 30 months for patients treated between 2016 and 2021, indicating a growing effectiveness of liver-directed therapies [5]. Adoption and Market Trends - The use of CHEMOSAT increased from eight patients between 2005 and 2015 to 30 patients between 2016 and 2021, reflecting its rising preference for treating metastatic uveal melanoma [6]. - The global liver metastases treatment market is estimated to reach $2.66 billion by 2030, growing at a CAGR of 7.3$1.74 billion in 2024, driven by the rising prevalence of liver metastases and advancements in therapeutic options [7][8]. Stock Performance - Delcath Systems' shares have risen 164.4% year to date, outperforming the industry growth of 10% and the S&P 500's rise of 18.4% during the same period [10].